About Randox Cardiology

Randox Cardiology is a division of Randox Laboratories Ltd, a privately owned international diagnostics manufacturer. Randox’s global headquarters are based in the UK, but we supply products to over 130 countries worldwide. Randox are a world class manufacture of biomarker solutions, whether it be for clinical practice or cutting edge research. In addition to a huge range of diagnostic reagents, such as H-FABP, Randox have also developed and manufactured Biochip Array Technology (BAT)™ – a pioneering biomarker multiplexing platform which enables simultaneous assessment of multiple biomarkers from a single patient blood sample. This technology has a massive range of potential applications, as demonstrated by the list of biomarker arrays available.

Applications of Biochip Array Technology

Available Biochip Protein Arrays

Molecular Diagnostic Arrays

Cardiac Risk Prediction Molecular Array
The Cardiac Risk Prediction Array provides simultaneous genotyping of 19 SNPs for a reliable CHD risk assessment. Combining genotype information with common risk factors could allow accurate classification of patients and preventative therapies and lifestyle advice targeted to those who require it most.
Familial Hypercholesterolemia (FH) Molecular Array
The Randox FH Array provides rapid simultaneous detection of mutations within the LDLR, ApoB and PCSK9 genes. FH is a genetic disorder of lipoprotein metabolism characterised by high LDL levels and early onset of cardiovascular disease.
Sexually Transmitted Infection (STI) Molecular Array
The Randox STI multiplex array rapidly screens for the presence of 10 different STIs simultaneously from one patient sample. The simultaneous detection of these infections provides a comprehensive profile for each patient enabling the clinician to decide on the best treatment options, decreasing antibiotic misuse and the risk of the infection spreading.
Respiratory Pathogen Molecular Array
The Randox Respiratory Pathogen Array is a multiplex array intended for the simultaneous detection of 22 respiratory pathogens in individuals suspected of Respiratory Tract Infections (RTIs).
KRAS, BRAF, PIK3CA Molecular Array
The KRAS, BRAF, PIK3CA Array allows the clinician to simultaneously detect important mutations in the KRAS, BRAF and PIK3CA genes, enabling the appropriate selection of metastatic CRC patients for therapy. For more information please visit www.randox.com or contact info@h-fabp.com

© 2013 Randox Laboratories Ltd. All rights reserved.